Good find carman2.

From what I see here vascular dimentia space is a highly competitive field. At least RVX made it to the list. I think it would require a highly skilled management team to be successful in this field. Unfortunately RVX management has achieved nothing since the failure of BoM and the management is far too weak to compete in this space. Just my opinion.

Hepalink doesn't even seem to be helping to move this compound forward.

It is a shame given the published science on alabetalone and the tremendous potential it offers.

GLTA.

Toinv